Loading…
Zenas BioPharma, Inc. is projected to rise to $45.76 by 2027, a +59% move from its current price of $28.74. ZBIO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $27.58 | $28.75 | $29.98 | +0.05% |
| Jul 14 | $27.12 | $28.77 | $30.52 | +0.10% |
| Jul 15 | $26.77 | $28.78 | $30.94 | +0.15% |
| Jul 16 | $26.49 | $28.80 | $31.31 | +0.20% |
| Jul 17 | $26.24 | $28.81 | $31.63 | +0.25% |
| Jul 18 | $26.02 | $28.83 | $31.93 | +0.30% |
| Jul 19 | $25.82 | $28.84 | $32.21 | +0.35% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $25.82 | $28.84 | $32.21 | +0.35% |
| Week 2 | $24.75 | $28.94 | $33.84 | +0.70% |
| Week 3 | $23.98 | $29.04 | $35.17 | +1.06% |
| Week 4 | $23.37 | $29.15 | $36.36 | +1.41% |
| Week 5 | $22.84 | $29.25 | $37.45 | +1.77% |
| Week 6 | $22.39 | $29.35 | $38.48 | +2.13% |
| Week 7 | $21.99 | $29.46 | $39.46 | +2.49% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Zenas BioPharma, Inc. is a clinical-stage biopharma company that engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023.
The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Zenas BioPharma, Inc. (ZBIO) is a Healthcare stock with a current price of $28.00 and a market cap of $1.77B. It is ranked 2160 in market capitalization. The stock sits in the Healthcare category as described in its profile.
The price outlook provided by the forecast shows a path of growth over the coming years, with a 2026 average price of $28.00 and long-term upside to the mid-to-high hundreds in the 2040s and 2050s. The numbers presented are estimates and not guarantees, reflecting a range of potential outcomes across multiple years.
A major floor 55.5% below — a decisive break under it would weaken the trend.
The nearest floor, 40.4% below — buyers have tended to step in here.
Price is pressing into resistance (2.4% away) — a breakout level to watch.
A major ceiling 30.1% above — clearing it would confirm fresh momentum.
Key ZBIO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ZBIO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $28.21 | Buy | $28.30 | Buy |
| MA 10 | $27.31 | Buy | $26.97 | Buy |
| MA 20 | $23.67 | Buy | $24.74 | Buy |
| MA 50 | $20.76 | Buy | $22.33 | Buy |
| MA 100 | $21.76 | Buy | $22.20 | Buy |
| MA 200 | $25.12 | Buy | $22.01 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 70.07 | Sell |
| Stoch RSI (14) | 71.36 | Neutral |
| CCI (20) | 90.38 | Neutral |
| Williams %R (14) | -7.48 | Info |
| MACD (12,26,9) | 0.54 | Buy |
| ROC (12) | 42.24 | Buy |
| Bollinger %B (20,2) | 0.82 | Neutral |
| Stochastic %K (14) | 92.52 | Sell |
| TRIX (15) | 1.45 | Buy |
| Awesome (5,34) | 6.79 | Buy |
| Ultimate (7,14,28) | 73.30 | Sell |
| Momentum (10) | 4.07 | Buy |
| Aroon Osc (25) | 96.00 | Buy |
| Hull MA (9) | 29.36 | Sell |
| ADX (14) | 28.82 | Buy |
| ATR (14) | 0.96 | Info |
The 30-day technical picture is bullish, with sentiment labeled as BULLISH. The RSI(14) sits at 80, signaling strong near-term momentum.
The moving averages show the stock trading above the SMA50 at $19.67 and near the SMA200 at $24.86, indicating a positive trend. Key technical levels include a support at $17.13 and a resistance at $28.00. The 30-day price range spans from a low of $20.53 to a high of $38.19, illustrating fairly wide intraday volatility within a bullish context.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $15.20 | $28.74 | $44.72 | 0% | Neutral | |
| $34.64 | $45.76 | $64.91 | +59% | Bullish | |
| $36.13 | $49.93 | $74.65 | +74% | Bullish | |
| $37.95 | $54.50 | $84.85 | +90% | Bullish | |
| $40.97 | $60.88 | $98.04 | +112% | Bullish | |
| $44.06 | $67.57 | $112.03 | +135% | Bullish | |
| $57.78 | $91.28 | $155.35 | +218% | Bullish | |
| $66.83 | $108.61 | $189.20 | +278% | Bullish | |
| $72.86 | $121.67 | $216.55 | +323% | Bullish | |
| $78.40 | $134.41 | $244.01 | +368% | Bullish | |
| $119.76 | $232.28 | $457.62 | +708% | Bullish | |
| $195.83 | $435.18 | $963.22 | +14.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $15.20 | $28.74 | $35.86 | +0.00% |
| August 2026 | $25.62 | $30.67 | $38.02 | +6.73% |
| September 2026 | $24.86 | $30.09 | $37.91 | -1.92% |
| October 2026 | $25.12 | $30.70 | $39.22 | +2.03% |
| November 2026 | $26.91 | $33.14 | $42.83 | +7.95% |
| December 2026 | $27.59 | $34.23 | $44.72 | +3.31% |
Click any year to see its month-by-month ZBIO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ZBIO is projected to trade between $15.20 and $44.72, averaging $28.74 — a potential gain of 0% from today's $28.74. A consolidation phase looks the most probable path here.
Zenas BioPharma, Inc.'s 2027 outlook centres on $45.76, within a $34.64 to $64.91 range. That is up +59% on the projected 2026 average. That marks a +59% change versus current levels. Momentum favours further upside here.
By 2028, ZBIO could reach as high as $74.65, with a base case around $49.93 and support toward $36.13 — roughly +74% from $28.74. Buyers look set to stay in control over this stretch.
Expect ZBIO to range from $37.95 to $84.85 through 2029. The $54.50 average target implies a +90% move from current prices. That is up +9% on the projected 2028 average. Momentum favours further upside here.
The ZBIO price prediction for 2030 points to an average of $60.88 (low $40.97, high $98.04) — a potential gain of +112% on today's $28.74. Buyers look set to stay in control over this stretch.
In 2031, ZBIO is projected to trade between $44.06 and $112.03, averaging $67.57 — a potential gain of +135% from today's $28.74. That is up +11% on the projected 2030 average. Momentum favours further upside here.
Zenas BioPharma, Inc.'s 2032 outlook centres on $91.28, within a $57.78 to $155.35 range. That is up +35% on the projected 2031 average. That marks a +218% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, ZBIO could reach as high as $189.20, with a base case around $108.61 and support toward $66.83 — roughly +278% from $28.74. Momentum favours further upside here.
Expect ZBIO to range from $72.86 to $216.55 through 2034. The $121.67 average target implies a +323% move from current prices. That is up +12% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The ZBIO price prediction for 2035 points to an average of $134.41 (low $78.40, high $244.01) — a potential gain of +368% on today's $28.74. Momentum favours further upside here.
In 2040, ZBIO is projected to trade between $119.76 and $457.62, averaging $232.28 — a potential gain of +708% from today's $28.74. That is up +73% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Zenas BioPharma, Inc.'s 2050 outlook centres on $435.18, within a $195.83 to $963.22 range. That is up +87% on the projected 2040 average. That marks a +14.1x change versus current levels. Momentum favours further upside here.
Investing $1,000 in ZBIO today (≈ 34.794711 ZBIO) could be worth
$15,142.05
+$14,142.05 (+1414%) by 2050 · US Dollar
Based on the average projected ZBIO price of $435.18 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ZBIOwould be worth at today's price.
$1,000 invested in ZBIO on Jul 10, 2025 (≈ 82.850044 ZBIO) would be worth
$2,381.11
+$1,381.11 (+138.1%) today · 2.38× · US Dollar
Based on a ZBIO entry price of $12.07 vs. today's $28.74.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $27.23 | $1,055.45 | +5.5% |
| 1 month ago | $17.91 | $1,604.69 | +60.5% |
| 3 months ago | $20.44 | $1,406.07 | +40.6% |
| 6 months ago | $19.78 | $1,452.98 | +45.3% |
| 1 year ago | $12.07 | $2,381.11 | +138.1% |
| All time (1.8y) ago | $18.15 | $1,583.47 | +58.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ZBIO forecast.
Our base-case forecast reaches $57.00 around 2030.
Implied market cap at $57.00: $3.6B
The multi-year forecast presents a bullish trajectory across the horizon, beginning with a 2026 average price of $28.00 and a neutral sentiment for that year. The subsequent years show rising averages and positive ROI, reinforcing an overall bullish outlook.
From 2027 through 2029, the forecast shows steady gains: 2027 avg $45.36, 2028 avg $49.11, 2029 avg $51.18 with ROI values of 62, 75.4, and 82.8 respectively, all maintaining a bullish sentiment. By 2030, the avg rises to $58.16 with a min of $37.65 and a max of $97.08, and ROI of 107.7, while sentiment remains BULLISH. The forecast continues to 2031–2035, with 2031 avg $63.56 and 2032 avg $84.32; 2033 avg $104.20; 2034 avg $115.87; 2035 avg $123.07, all with bullish sentiment and expanding price potential.
Looking farther ahead, the 2040 forecast shows an avg of $215.26 with a min of $101.21 and a max of $446.44, delivering an ROI of 668.8 and a bullish sentiment. By 2050, the avg reaches $383.52 with a min of $172.58 and a max of $882.09, delivering an ROI of 1269.7 and continuing the bullish stance. These figures illustrate a long-run growth scenario, though they are estimates and not guarantees.
Drivers and risks are inherent in such long-horizon projections, and actual outcomes may differ.
Tap a question to reveal the answer.
Avg $58.16, min $37.65, max $97.08; ROI 107.7; sentiment BULLISH.
The forecast shows a bullish sentiment from 2027 onward with rising averages: 2027 $45.36, 2028 $49.11, 2029 $51.18, 2030 $58.16, 2040 $215.26, 2050 $383.52, and positive ROI values (62, 75.4, 82.8, 107.7, 668.8, 1269.7). The 2026 forecast is Neutral.
Yes. The forecast max for 2032 is $149.41, and the 2030 max is $97.08 with 2031 max $109.50, indicating potential to surpass $100 in the forecast horizon.
Current price $28.00; Market cap $1.77B.
Sentiment BULLISH; RSI(14) 80; SMA50 $19.67; SMA200 $24.86; Support $17.13; Resistance $28.00; 30-day range low $20.53, high $38.19.
Zenas BioPharma, Inc. Community Discussion
0Share your Zenas BioPharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.